A fully humanized IgG-like bispecific antibody for effective dual targeting of CXCR3 and CCR6.

Chemokines and their receptors are pivotal for the trafficking of leukocytes during immune responses, and host defense. However, immune cell migration also contributes to a wide variety of autoimmune and chronic inflammatory diseases. Compelling evidence suggests that both CXCR3 and CCR6 chemokine r...

Full description

Saved in:
Bibliographic Details
Main Authors: Remy Robert, Laurent Juglair, Ee X Lim, Caroline Ang, Carl J H Wang, Gregor Ebert, Olan Dolezal, Charles R Mackay
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2017-01-01
Series:PLoS ONE
Online Access:https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0184278&type=printable
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850230239461900288
author Remy Robert
Laurent Juglair
Ee X Lim
Caroline Ang
Carl J H Wang
Gregor Ebert
Olan Dolezal
Charles R Mackay
author_facet Remy Robert
Laurent Juglair
Ee X Lim
Caroline Ang
Carl J H Wang
Gregor Ebert
Olan Dolezal
Charles R Mackay
author_sort Remy Robert
collection DOAJ
description Chemokines and their receptors are pivotal for the trafficking of leukocytes during immune responses, and host defense. However, immune cell migration also contributes to a wide variety of autoimmune and chronic inflammatory diseases. Compelling evidence suggests that both CXCR3 and CCR6 chemokine receptors play crucial roles in the migration of pathological Th1 and Th17 cells during the course of certain inflammatory diseases. The use of two or more receptors by pathogenic cells may explain why targeting of individual receptors has proven disappointing in the clinic. We therefore hypothesized that simultaneous targeting of both CXCR3 and CCR6 with a bispecific antibody (BsAb) might result in decreased chemotaxis and/or specific depletion of pro-inflammatory T cell subsets. In this study, we designed and characterized a fully humanized BsAb. We show that the BsAb binds to both chemokine receptors, as demonstrated by Flow Cytometry and Surface Plasmon Resonance analysis. Furthermore, we demonstrate that the BsAb effectively blocks cell chemotaxis and induces specific antibody-dependent cell-mediated cytotoxicity (ADCC) in vitro. Therefore, we propose that dual targeting of CXCR3 and CCR6 with a fully humanized BsAb may display a potent interventional approach for the treatment of inflammatory and autoimmune diseases.
format Article
id doaj-art-8708c0d0b60b4ff4808743979a159753
institution OA Journals
issn 1932-6203
language English
publishDate 2017-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj-art-8708c0d0b60b4ff4808743979a1597532025-08-20T02:03:55ZengPublic Library of Science (PLoS)PLoS ONE1932-62032017-01-01129e018427810.1371/journal.pone.0184278A fully humanized IgG-like bispecific antibody for effective dual targeting of CXCR3 and CCR6.Remy RobertLaurent JuglairEe X LimCaroline AngCarl J H WangGregor EbertOlan DolezalCharles R MackayChemokines and their receptors are pivotal for the trafficking of leukocytes during immune responses, and host defense. However, immune cell migration also contributes to a wide variety of autoimmune and chronic inflammatory diseases. Compelling evidence suggests that both CXCR3 and CCR6 chemokine receptors play crucial roles in the migration of pathological Th1 and Th17 cells during the course of certain inflammatory diseases. The use of two or more receptors by pathogenic cells may explain why targeting of individual receptors has proven disappointing in the clinic. We therefore hypothesized that simultaneous targeting of both CXCR3 and CCR6 with a bispecific antibody (BsAb) might result in decreased chemotaxis and/or specific depletion of pro-inflammatory T cell subsets. In this study, we designed and characterized a fully humanized BsAb. We show that the BsAb binds to both chemokine receptors, as demonstrated by Flow Cytometry and Surface Plasmon Resonance analysis. Furthermore, we demonstrate that the BsAb effectively blocks cell chemotaxis and induces specific antibody-dependent cell-mediated cytotoxicity (ADCC) in vitro. Therefore, we propose that dual targeting of CXCR3 and CCR6 with a fully humanized BsAb may display a potent interventional approach for the treatment of inflammatory and autoimmune diseases.https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0184278&type=printable
spellingShingle Remy Robert
Laurent Juglair
Ee X Lim
Caroline Ang
Carl J H Wang
Gregor Ebert
Olan Dolezal
Charles R Mackay
A fully humanized IgG-like bispecific antibody for effective dual targeting of CXCR3 and CCR6.
PLoS ONE
title A fully humanized IgG-like bispecific antibody for effective dual targeting of CXCR3 and CCR6.
title_full A fully humanized IgG-like bispecific antibody for effective dual targeting of CXCR3 and CCR6.
title_fullStr A fully humanized IgG-like bispecific antibody for effective dual targeting of CXCR3 and CCR6.
title_full_unstemmed A fully humanized IgG-like bispecific antibody for effective dual targeting of CXCR3 and CCR6.
title_short A fully humanized IgG-like bispecific antibody for effective dual targeting of CXCR3 and CCR6.
title_sort fully humanized igg like bispecific antibody for effective dual targeting of cxcr3 and ccr6
url https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0184278&type=printable
work_keys_str_mv AT remyrobert afullyhumanizedigglikebispecificantibodyforeffectivedualtargetingofcxcr3andccr6
AT laurentjuglair afullyhumanizedigglikebispecificantibodyforeffectivedualtargetingofcxcr3andccr6
AT eexlim afullyhumanizedigglikebispecificantibodyforeffectivedualtargetingofcxcr3andccr6
AT carolineang afullyhumanizedigglikebispecificantibodyforeffectivedualtargetingofcxcr3andccr6
AT carljhwang afullyhumanizedigglikebispecificantibodyforeffectivedualtargetingofcxcr3andccr6
AT gregorebert afullyhumanizedigglikebispecificantibodyforeffectivedualtargetingofcxcr3andccr6
AT olandolezal afullyhumanizedigglikebispecificantibodyforeffectivedualtargetingofcxcr3andccr6
AT charlesrmackay afullyhumanizedigglikebispecificantibodyforeffectivedualtargetingofcxcr3andccr6
AT remyrobert fullyhumanizedigglikebispecificantibodyforeffectivedualtargetingofcxcr3andccr6
AT laurentjuglair fullyhumanizedigglikebispecificantibodyforeffectivedualtargetingofcxcr3andccr6
AT eexlim fullyhumanizedigglikebispecificantibodyforeffectivedualtargetingofcxcr3andccr6
AT carolineang fullyhumanizedigglikebispecificantibodyforeffectivedualtargetingofcxcr3andccr6
AT carljhwang fullyhumanizedigglikebispecificantibodyforeffectivedualtargetingofcxcr3andccr6
AT gregorebert fullyhumanizedigglikebispecificantibodyforeffectivedualtargetingofcxcr3andccr6
AT olandolezal fullyhumanizedigglikebispecificantibodyforeffectivedualtargetingofcxcr3andccr6
AT charlesrmackay fullyhumanizedigglikebispecificantibodyforeffectivedualtargetingofcxcr3andccr6